Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Apr;60(3):1633-1643.
doi: 10.1007/s00394-020-02361-7. Epub 2020 Aug 14.

Effect of 2 years of calorie restriction on liver biomarkers: results from the CALERIE phase 2 randomized controlled trial

Affiliations
Clinical Trial

Effect of 2 years of calorie restriction on liver biomarkers: results from the CALERIE phase 2 randomized controlled trial

James L Dorling et al. Eur J Nutr. 2021 Apr.

Abstract

Purpose: Calorie restriction (CR) is an effective treatment for obesity-related liver and metabolic disease. However, CR studies in individuals without obesity are needed to see if CR could delay disease onset. Liver biomarkers indicate hepatic health and are linked to cardiometabolic disease. Our aim was to examine the effects of a 2-year CR intervention on liver biomarkers in healthy individuals without obesity.

Methods: The Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy (CALERIE) study was a 2-year randomized controlled trial. Overall, 218 participants (body mass index: 25.1 ± 1.7 kg/m2) were enrolled into a control group (n = 75) that ate ad libitum (AL), or a CR group (n = 143) that aimed to decrease energy intake by 25%. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and bilirubin were measured during the trial.

Results: At month 24, relative to the AL group, ALP (- 7 ± 1 IU/L; P < 0.01) and GGT (- 0.11 ± 0.04 log IU/L; P = 0.02) decreased and bilirubin increased (0.21 ± 0.06 log mg/dL; P < 0.01) in the CR group; no between-group differences in ALT (- 1 ± 1 IU/L; P > 0.99) or AST (2 ± 2 IU/L; P = 0.68) were revealed. However, sex-by-treatment-by-time interactions (P < 0.01) were observed, with CR (vs. control) inducing reduced ALT and GGT and increased AST in men only (P ≤ 0.02).

Conclusions: In metabolically healthy individuals without obesity, 2 years of CR improves several liver biomarkers, with potentially greater improvements in men. These data suggest that sustained CR may improve long-term liver and metabolic disease risk in healthy adults.

Trial registration: Clinicaltrials.gov (NCT00427193). Registered January 2007.

Keywords: Aging; Bilirubin; Cardiometabolic health; Energy restriction; Liver enzymes.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest/Competing interests: All authors declare no conflicts of interest relevant to the study.

Figures

Fig. 1
Fig. 1
CALERIE phase 2 CONSORT diagram
Fig. 2
Fig. 2
Adjusted changes in alanine amino transferase (ALT; a & b), aspartate aminotransferase (AST; c & d) and gamma-glutamyl transferase (GGT; e & f) in men and women during CALERIE phase 2. Dashed lines represent calorie restriction (CR), whereas solid lines represent ad libitum (AL) control group. *P < 0.05 between CR and AL groups

Similar articles

Cited by

References

    1. Sheedfar F, Biase S Di, Koonen D, Vinciguerra M (2013) Liver diseases and aging: Friends or foes? Aging Cell 12:950–954. 10.1111/acel.12128 - DOI - PubMed
    1. Younossi ZM, Koenig AB, Abdelatif D, et al. (2016) Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84. 10.1002/hep.28431 - DOI - PubMed
    1. Byrne CD, Targher G (2015) NAFLD: A multisystem disease. Journal of Hepatology 62:S47–S64. 10.1016/j.jhep.2014.12.012 - DOI - PubMed
    1. Kumashiro N, Erion DM, Zhang D, et al. (2011) Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proceedings of the National Academy of Sciences of the United States of America 108:16381–16385. 10.1073/pnas.1113359108 - DOI - PMC - PubMed
    1. Day CP (2002) Pathogenesis of steatohepatitis. Best Practice and Research in Clinical Gastroenterology 16:663–678. 10.1053/bega.2002.0333 - DOI - PubMed

Publication types

Associated data